Juan Jesús
Gómez-Reino Carnota
University Hospital of Geneva
Ginebra, SuizaPublicacións en colaboración con investigadores/as de University Hospital of Geneva (14)
2022
-
After JAK inhibitor failure: To cycle or to switch, that is the question - Data from the JAK-pot collaboration of registries
Annals of the Rheumatic Diseases, Vol. 82, Núm. 2, pp. 175-181
2019
-
Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration
Annals of the Rheumatic Diseases, Vol. 78, Núm. 11, pp. 1536-1544
2018
-
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
The Lancet, Vol. 391, Núm. 10136, pp. 2213-2224
2017
-
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Annals of the Rheumatic Diseases, Vol. 76, Núm. 6, pp. 960-977
-
Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis
Rheumatology (United Kingdom), Vol. 56, Núm. 5, pp. 689-697
-
Rituximab retreatment in rheumatoid arthritis in a real-life cohort: Data from the CERERRA collaboration
Journal of Rheumatology, Vol. 44, Núm. 2, pp. 162-169
2016
-
Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: Data from the CERERRA collaboration
Arthritis Research and Therapy, Vol. 18, Núm. 1
-
Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: Data from the CERERRA collaboration [Arthritis Res Ther. 18: (2016); 50], doi: 10.1186/s13075-016-0951-z
Arthritis Research and Therapy
2013
-
Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: Systematic literature review and meta-analysis informing a consensus statement
Annals of the Rheumatic Diseases, Vol. 72, Núm. 4, pp. 583-589
-
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions
Annals of the Rheumatic Diseases, Vol. 72, Núm. 4, pp. 482-492
2012
-
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: Results of a 1-year follow-up study from the CERERRA collaboration
Annals of the Rheumatic Diseases, Vol. 71, Núm. 3, pp. 374-377
2011
-
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: Pooled data from 10 European registries
Annals of the Rheumatic Diseases, Vol. 70, Núm. 9, pp. 1575-1580
2010
-
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Annals of the Rheumatic Diseases, Vol. 69, Núm. 6, pp. 964-975
2007
-
Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis
Rheumatology International, Vol. 27, Núm. 9, pp. 793-806